UBS Group
RLMD icon

UBS Group’s Relmada Therapeutics RLMD Stock Holding History

UBS Group’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$882K Buy
126,672
+85,204
+205% +$403K ﹤0.01% 5651
2025
Q4 		$200K Sell
41,468
-18,317
-31% -$61.4K ﹤0.01% 6579
2025
Q3 		$120K Sell
59,785
-120,686
-67% -$116K ﹤0.01% 6996
2025
Q2 		$108K Buy
180,471
+35,682
+25% +$18.3K ﹤0.01% 7171
2025
Q1 		$39.1K Sell
144,789
-70,351
-33% -$23.3K ﹤0.01% 7765
2024
Q4 		$112K Buy
215,140
+88,755
+70% +$216K ﹤0.01% 6801
2024
Q3 		$409K Sell
126,385
-2,415
-2% -$7.82K ﹤0.01% 5370
2024
Q2 		$386K Sell
128,800
-485
-0.4% -$1.75K ﹤0.01% 5198
2024
Q1 		$601K Buy
129,285
+3,555
+3% +$17.1K ﹤0.01% 5044
2023
Q4 		$521K Buy
125,730
+42
+0% +$124 ﹤0.01% 5071
2023
Q3 		$377K Buy
125,688
+26,700
+27% +$79.3K ﹤0.01% 4877
2023
Q2 		$244K Buy
98,988
+97,410
+6,173% +$269K ﹤0.01% 5355
2023
Q1 		$3.57K Sell
1,578
-4,335
-73% -$14.9K ﹤0.01% 8301
2022
Q4 		$20.6K Sell
5,913
-171
-3% -$1.5K ﹤0.01% 7620
2022
Q3 		$225K Buy
6,084
+4,756
+358% +$132K ﹤0.01% 4986
2022
Q2 		$25K Hold
1,328
– – ﹤0.01% 6612
2022
Q1 		$36K Sell
1,328
-1,869
-58% -$38.6K ﹤0.01% 6825
2021
Q4 		$72K Sell
3,197
-1,522
-32% -$33.8K ﹤0.01% 6597
2021
Q3 		$124K Buy
4,719
+98
+2% +$2.62K ﹤0.01% 5671
2021
Q2 		$148K Sell
4,621
-1,925
-29% -$66.9K ﹤0.01% 5580
2021
Q1 		$230K Sell
6,546
-873
-12% -$30.5K ﹤0.01% 5385
2020
Q4 		$238K Buy
7,419
+1,805
+32% +$62K ﹤0.01% 5135
2020
Q3 		$211K Sell
5,614
-2,747
-33% -$106K ﹤0.01% 4770
2020
Q2 		$374K Buy
8,361
+5,318
+175% +$225K ﹤0.01% 4362
2020
Q1 		$104K Sell
3,043
-1,214
-29% -$48.9K ﹤0.01% 5260
2019
Q4 		$166K Buy
+4,257
New +$129K ﹤0.01% 5718

Other funds holding RLMD

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
SSC
Spruce Street Capital New York $416M AUM
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

UBS Group's RLMD Position: Q1 2026 in Review

UBS Group increased its Relmada Therapeutics (RLMD) stake by 205% in Q1 2026, buying an estimated $403K and bringing the position to 126,672 shares worth $882K. The position accounts for ﹤0.01% of the portfolio, ranked #5651.

UBS Group first reported a position in RLMD in Q4 2019 and has held it in 26 quarters since. 103 funds tracked by Wall St. Rank hold RLMD as of Q1 2026.

  • UBS Group held 126,672 shares of Relmada Therapeutics worth $882K as of Q1 2026.
  • UBS Group bought 85,204 Relmada Therapeutics shares in Q1 2026, an estimated $403K.
  • Relmada Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #5651 holding.
  • UBS Group first reported a position in Relmada Therapeutics in Q4 2019 and has held it in 26 quarters since.
  • 103 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.